Aspects of tolerability of centrally acting antihypertensive drugs

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 3, 1996, Pages

  Webster, J ^a   Koch, H F ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Antihypertensives; Clonidine; Imidazoline agonists; Methyldopa; Reserpine; Side effects

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLONIDINE; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE; RESERPINE; RILMENIDINE;

CONFERENCE PAPER; COOMBS TEST; DROWSINESS; DRUG RECEPTOR BINDING; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMPOTENCE; LETHARGY; LIVER FUNCTION; NOSE SECRETION; PARKINSONISM; PRIORITY JOURNAL; SEDATION;

EID: 0029787839     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199627003-00007     Document Type: Conference Paper

References (29)

1. 1 receptor and the pharmacology of imidazolines. Cardiovasc Drugs Ther 1994;8:21-6.
2. Reis D. The rostral ventrolateral medulla: a target for therapy for hypertension. Cardiovasc Risk Factors 1995;5(suppl 1):11-8.
3. 1-imidazoline agonist. Cardiovasc Drugs Ther 1994;8:27-41.
4. 1-imidazoline receptor agonist moxonidine: a new antihypertensive. London: Royal Society of Medicine Services, 1994:1-23.
5. Feldman J, Tibirica E, Bricca G, Dontenwill M, Belcourt A, Bousquet P. Evidence for the involvement of imidazoline receptors in the central action of rilmenidine in the rabbit. Br J Pharmacol 1990;100:600-4.
6. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202: 1028-34.
7. Veterans Administration Cooperative Study Group on Anti-hypertensive Agents: Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213: 1143-52.
8. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. III Reduction in stroke incidence among persons with high blood pressure. JAMA 1982; 247:633-8.
9. Shapiro S, Parsells JL, Rosenberg L, et al. Risk of breast cancer in relation to the use of Rauwolfia alkaloids. Eur J Clin Pharmacol 1984;26:143-6.
10. Rauwolfia. Reserpine. In: Dollery CT, ed. Therapeutic drugs. Edinburgh: Churchill Livinstone, 1991;R9-R12.
11. Medical Research Council Working Party. MRC trial in mild hypertension: principal results. BMJ 1985;291:97-104.
12. Management Committee of the Australian National Blood Pressure Study. The Australian therapeutic trial in mild hypertension. Lancet 1980;2:1261.
13. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-54.
14. Croog SH, Levine S, Testa MA, et al. The effects of anti-hypertensive therapy on the quality of life. N Engl J Med 1986;314:1657-64.
15. Redman CWG, Beilin LJ, Bonnar J, Ounsted MK. Fetal outcome of antihypertensive treatment in pregnancy. Lancet 1976;2:753-6.
16. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. N Engl J Med 1993;328: 914-21.
17. Davies DS, Wing LMH, Reid JL, Neill E, Tippett P, Dollery CT. Pharmocokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 1977;21:593-601.
18. Hansson L, Hunyor SN, Julius S, Hoobler SW. Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J 1973;85:605-10.
19. Reid JL, Wing LMH, Dargie HJ, Hamilton CA, Davies DS, Dollery CT. Clonidine withdrawal in hypertension: changes in blood pressure and plasma and urinary noradrenaline. Lancet 1977;1:1171-1.
20. Vanholder R, Carpentier J, Schurgers M, Clement DL. Rebound phenomenon during gradual withdrawal of clonidine [Letter]. BMJ 1977;1:1138.
21. Webster J, Jeffers TA, Galloway DB, Petrie JC. Withdrawal of antihypertensive medication [Letter]. Lancet 1974;2: 1318.
22. Whitsett TI. Abrupt cessation of treatment with centrally acting antihypertensive agents. Chest 1983;83(suppl):400-2.
23. Kirch W, Hutt H-J, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration to hypertensive patients. J Clin Pharmacol 1990;30: 1088-95.
24. Ziegler G, Gemeinhardt A. CNS effects of moxonidine, a new central nervous system anti-hypertensive drug, in comparison with clonidine and placebo. Klin Wochenschr 1988; 66(suppl XIII):41-6.
25. Planitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol 1987; 27:46-51.
26. Schmidt U, Frerick H, Kraft K, Schenk N, Low-Kruger A. Hypertension: a possible risk in road traffic. J Cardiovasc Pharmacol 1992;20(suppl 4):s50-6.
27. Kaan H. Response risk/benefit moxonidine. Solvay Pharma Deutschland GMBH, Hannover, Germany, December 22, 1994 (data on file).
28. MacPhee GJA, Howie CA, Elliot HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol 1992;33:261-7.
29. Planitz V. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. Eur J Pharmacol 1984;27:147-52.